Monthly Communication Report

Corporation:	Moderna Biopharma Canada Corporation
Associated registration:	956349-370107-19
Communication date:	2025-09-19
Posted date:	2025-10-15

Designated Public Office Holders who participated in the communication:	Marjorie Michel, Minister of Health Public Health Agency of Canada (PHAC) Ritu Banerjee, Assistant Deputy Minister Director General's Office, Innovation, Science and Economic Development Canada (ISED) Andrea Gilpin, Chief of Staff Public Health Agency of Canada (PHAC) Philip Jennings, Deputy Minister Office of the Deputy Minister, Innovation, Science and Economic Development Canada (ISED) Nancy Hamzawi, President Public Health Agency of Canada (PHAC) Mélanie Joly, Minister of Innovation, Sciences and Economic Development Innovation, Science and Economic Development Canada (ISED) Natasha Crowcroft, Vice President Public Health Agency of Canada (PHAC)
List of Details Subject matter Detail Research and Development, Science and Technology Government policies regarding innovation, research and development, and messenger ribonucleic acid (mRNA) biotechnology Government Procurement, Health Health Canada and Public Services and Procurement Canada policies regarding the development, procurement, and distribution of Moderna’s COVID-19 vaccine to various segments of the population, including future distribution models Economic Development, Health The government’s Pandemic Preparedness Strategy as it relates to the corporation’s future operations in Canada
Responsible Officer who filed this communication report:	Stefan Raos
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.